Epithelioid sarcoma is a rare, aggressive cancer that forms in soft tissues, most often in the hands, forearms, or lower legs of young adults. It accounts for less than 1% of all soft tissue sarcomas, with an incidence of roughly 0.1 cases per million people per year. Despite its rarity, it’s important to understand because it frequently mimics harmless conditions like cysts or slow-healing wounds, which can delay diagnosis for months or even years.
How Epithelioid Sarcoma Differs From Other Sarcomas
Most soft tissue sarcomas fall into categories based on the type of tissue they resemble, such as fat, muscle, or nerve. Epithelioid sarcoma doesn’t fit neatly into any of these. The World Health Organization classifies it as a “tumor of uncertain differentiation” because its cells show features of both epithelial tissue (the type that lines your skin and organs) and mesenchymal tissue (the connective tissue that forms muscle, bone, and cartilage). This dual nature is part of what makes it tricky to identify under a microscope.
The tumor typically forms firm, slow-growing nodules that can sit just beneath the skin or deeper within tendons and connective tissue. Because these lumps often look and feel like benign cysts, granulomas, or warts, they’re frequently misdiagnosed at first. Some tumors ulcerate through the skin, resembling a wound that won’t heal. This deceptive appearance is one of the biggest clinical challenges with the disease.
The Two Subtypes
Epithelioid sarcoma comes in two forms, defined largely by where in the body they appear and how aggressively they behave.
The distal type (also called classic or conventional) is the more common form. It typically develops in the fingers, hands, wrists, forearms, or lower legs. It tends to affect teenagers and young adults and grows relatively slowly, though it has a strong tendency to recur after removal.
The proximal type was identified more recently and tends to arise in deeper tissues closer to the trunk: the pelvis, groin, buttocks, or upper thighs. It generally occurs in older adults and behaves more aggressively, with larger tumors and a higher risk of spreading to distant organs. Proximal-type tumors can be especially difficult to distinguish from other aggressive cancers under the microscope.
Who Gets It
Epithelioid sarcoma predominantly affects young adults in their teens, twenties, and thirties, though it can occur at any age. Men are affected roughly twice as often as women. In children, it makes up about 4 to 8% of non-rhabdomyosarcoma soft tissue tumors, making it relatively more significant in pediatric oncology than its overall rarity might suggest.
The Genetic Driver Behind It
Nearly all epithelioid sarcomas share a specific genetic defect: the complete loss of a tumor-suppressor protein called INI1, produced by the SMARCB1 gene. This protein normally helps regulate how tightly DNA is packaged inside cells, which in turn controls which genes get switched on or off. When INI1 is absent, cells lose a critical brake on growth.
This loss is so consistent in epithelioid sarcoma that testing for it has become a key part of confirming the diagnosis. Pathologists can stain a tissue sample for INI1 protein. If it’s completely absent from tumor cells while still present in surrounding normal cells, that strongly supports the diagnosis. Very few other tumor types show this pattern, which makes it a powerful diagnostic tool when the microscopic appearance alone is ambiguous.
How It’s Diagnosed
Diagnosis starts with a biopsy, where a sample of the suspicious tissue is examined under a microscope. Epithelioid sarcoma cells form characteristic clusters or nodules, sometimes with dead tissue at the center. But because the cells can resemble those found in infections, inflammatory conditions, or other cancers, additional testing is essential.
Pathologists use a panel of specialized stains to confirm the diagnosis. The tumor cells typically test positive for markers associated with epithelial cells (cytokeratin and epithelial membrane antigen) as well as a marker called CD34, which is more commonly seen in blood vessel tumors. The combination of these positive markers alongside the absence of INI1 protein creates a diagnostic fingerprint that separates epithelioid sarcoma from its many look-alikes.
Survival by Stage at Diagnosis
Prognosis depends heavily on how far the disease has spread at the time of diagnosis. A study of 441 cases from the U.S. SEER cancer database found clear differences across stages:
- Localized disease (tumor confined to the original site): 75% five-year survival
- Regional disease (spread to nearby lymph nodes or tissues): 49% five-year survival
- Distant disease (spread to other organs): no patients in the study survived five years, and only 46% survived one year
These numbers underscore how much early detection matters. Unfortunately, the tumor’s tendency to mimic benign conditions means many people don’t receive a correct diagnosis until the disease has had time to progress.
Recurrence and Spread
One of the most frustrating features of epithelioid sarcoma is its high rate of local recurrence. Even after complete surgical removal, the tumor frequently comes back in the same area, sometimes multiple times. This is partly because the cancer tends to travel along tendons, nerves, and connective tissue planes, making it difficult to ensure every microscopic extension has been removed.
When the disease does metastasize, the lungs are the most common destination. Lymph node involvement is also relatively common compared to other soft tissue sarcomas, which rarely spread through the lymphatic system. The scalp, brain, and other soft tissues are less frequent but documented sites of distant spread.
Surgical Treatment
Surgery is the primary treatment. The goal is to remove the tumor with a margin of healthy tissue around it, reducing the chance that cancer cells are left behind. In practice, surgeons aim for a clear (negative) margin, meaning no tumor is visible at the cut edge of the removed tissue. A margin of less than 1 centimeter is generally considered “close,” and in some cases the margin may be microscopically positive, meaning tiny amounts of tumor reach the edge.
For tumors in the arms or legs, limb-sparing surgery is the standard approach whenever possible. Surgeons balance the need for wide margins against the goal of preserving function. When the margin is close or positive, radiation therapy before or after surgery can help reduce the risk of local recurrence. Intact layers of fascia (the tough membranes surrounding muscles) can serve as natural barriers, sometimes allowing for narrower margins without compromising outcomes.
Targeted Therapy for Advanced Disease
For patients whose tumors can’t be fully removed surgically or have already spread, a targeted drug called tazemetostat offers a treatment option that directly addresses the genetic defect driving the cancer. In January 2020, the FDA granted accelerated approval for tazemetostat in adults and patients 16 and older with metastatic or locally advanced epithelioid sarcoma that isn’t eligible for complete surgical removal.
Tazemetostat works by blocking an enzyme called EZH2. When the INI1 protein is missing, EZH2 becomes overactive, essentially silencing genes that would normally slow cell growth. By inhibiting EZH2, the drug restores some of that lost control. It was the first drug targeting this specific epigenetic mechanism to be approved for any solid tumor. The approval was based on the drug’s ability to shrink tumors and maintain that response over time, and its side effect profile is generally considered manageable compared to traditional chemotherapy.
Researchers are also investigating whether combining tazemetostat with standard chemotherapy or immune checkpoint inhibitors could improve outcomes. Early laboratory data suggests the drug may work synergistically with chemotherapy agents, and there’s evidence that it can boost the immune system’s ability to recognize tumor cells, potentially making immunotherapy more effective. Clinical trials testing these combinations are underway.